FDA expands nivolumab approval

20 Oct 2015 12:45 PM | Lori Aubrey (Administrator)

FDA approved nivolumab (Opdivo  Injection, Bristol-Myers Squibb Company), for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.  Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo.  October 9, 2015  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm466576.htm

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software